MedLife invests EUR 3 million in genetic testing, becoming a leader in personalized medicine in Romania with the aim to improve quality of life.
Delia Niculescu
Current Affairs
foto:shutterstock
Always see our news on Google
MedLife is to launch an innovative genetic testing program, with an initial investment of €3 million, aimed at facilitating access to individual genetic mapping and promoting personalized medicine. The project will involve over 4,000 beneficiaries and will use Illumina NovaSeq X Plus sequencing technology, one of the most advanced in the world. This initiative marks an important transition in the Romanian medical system, aiming at prevention and personalization of treatments according to genetic profile. MedLife, with more than 20 years of experience in genetics, thus confirms its leading role in the field and its commitment to improve the health of the population.
Sources
Premieră în România. MedLife aduce cea mai avansată tehnologie de secvențiere și pregătește un program amplu de testare genetică: “Începând cu luna octombrie, pe teritoriul României se va putea realiza secvențierea întregului genom uman la scară largă”
Secvențierea întregului genom uman la scară largă se va putea face în România, din octombrie - Economica.net
Latest News
22:59
Dominic Fritz rejects the idea of an independent prime minister and calls for snap elections if a political solution does not emerge quickly
22:45
The MFA warns that Serbian transporters will block the border with the EU, and freight traffic will be halted for an indefinite period
22:42
Dominic Fritz calls for a broad coalition against the PSD-AUR alliance and rules out a merger between USR and PNL
22:34
Cseke Attila Calls for the Rapid Installation of a Government with Full Powers for the Budget Revision Needed in Healthcare
22:18
BVB ended Thursday’s session down. The value of transactions exceeded 100 million lei
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
